全文获取类型
收费全文 | 6187篇 |
免费 | 499篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 331篇 |
妇产科学 | 159篇 |
基础医学 | 864篇 |
口腔科学 | 137篇 |
临床医学 | 813篇 |
内科学 | 1073篇 |
皮肤病学 | 83篇 |
神经病学 | 467篇 |
特种医学 | 483篇 |
外科学 | 779篇 |
综合类 | 188篇 |
一般理论 | 6篇 |
预防医学 | 551篇 |
眼科学 | 66篇 |
药学 | 350篇 |
1篇 | |
中国医学 | 6篇 |
肿瘤学 | 346篇 |
出版年
2023年 | 43篇 |
2022年 | 54篇 |
2021年 | 171篇 |
2020年 | 91篇 |
2019年 | 139篇 |
2018年 | 174篇 |
2017年 | 122篇 |
2016年 | 150篇 |
2015年 | 155篇 |
2014年 | 183篇 |
2013年 | 250篇 |
2012年 | 304篇 |
2011年 | 392篇 |
2010年 | 191篇 |
2009年 | 216篇 |
2008年 | 240篇 |
2007年 | 270篇 |
2006年 | 264篇 |
2005年 | 271篇 |
2004年 | 219篇 |
2003年 | 201篇 |
2002年 | 186篇 |
2001年 | 122篇 |
2000年 | 125篇 |
1999年 | 133篇 |
1998年 | 149篇 |
1997年 | 145篇 |
1996年 | 150篇 |
1995年 | 107篇 |
1994年 | 108篇 |
1993年 | 124篇 |
1992年 | 70篇 |
1991年 | 86篇 |
1990年 | 73篇 |
1989年 | 94篇 |
1988年 | 98篇 |
1987年 | 58篇 |
1986年 | 82篇 |
1985年 | 71篇 |
1984年 | 64篇 |
1983年 | 57篇 |
1982年 | 54篇 |
1981年 | 56篇 |
1980年 | 44篇 |
1979年 | 41篇 |
1978年 | 29篇 |
1977年 | 33篇 |
1976年 | 24篇 |
1974年 | 28篇 |
1973年 | 34篇 |
排序方式: 共有6723条查询结果,搜索用时 421 毫秒
1.
2.
3.
4.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
5.
Birth weight on 12,644 singleton infants from 6,196 sibships born in Maryland between 1980 and 1984 were used to estimate the effects of nine maternal and infant covariates on the sibship correlation in birth weight. Assuming a homogeneous correlation across all families, the estimated intraclass correlation was 0.4664 (+/- 0.0099). This high sibship correlation makes it possible to predict, with reasonable accuracy, the birth weight of a child given information on previous sibs, as well as covariates on the mother and/or infant pertinent to a given pregnancy. The reduction in variance associated with incorporating information on the nine covariates used here was approximately equal to that obtained by conditioning on a single previous sib. Testing for heterogeneity in correlation among different groups of families showed that a crude measure of parity (first live birth vs. other), time between births, mother's marital status, and maternal age at the birth of the last child significantly influenced the sibship correlation in birth weight. 相似文献
6.
7.
8.
9.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
10.